 
|
Review Articles
|
McKinnon PS, Davis SL. Pharmacokinetic and Pharmacodynamic Issues
in the Treatment of Bacterial Infectious Diseases.
|
|
|
Nuermberger E, Grosset J, Peloquin CA. Pharmacokinetic and Pharmacodynamic Issues
in the Treatment of Mycobacterial Infections.
|
|
|
Groll AH, Kolve H. Antifungal Agents: In vitro Susceptibility
Testing, Pharmacodynamics, and Prospects for Combination Therapy.
|
|
|
Morse GD, Catanzaro L, Acosta E. Optimizing Clinical Pharmacodynamics of
HIV-1 Protease Inhibitors with Inhibitory Quotients.
|
|
|
Edwards G, Krishna S. Pharmacokinetic and pharmacodynamic Issues
in the Treatment of Parasitic Infections.
|
|
|
|
Franco-Paredes
C,
Santos-Preciado JI. Problem
pathogens: prevention of malaria in travelers.
|
|
|
|
Rybak M, LaPlante K.
Community-Associated
Methicillin-Resistant Staphylococcus aureus: A Review.
|
|
|
|
Hiramatsu
K. Vancomycin-resistant Staphylococcus aureus: a new model of
antibiotic resistance.
|
|
|
|
Lynn WA,
Lightman S. Syphilis
and HIV: a dangerous combination.
|
|
|
|
Singh, N. Treatment
of opportunistic mycoses: how long is long enough?
|
|
|
|
Webster RG,
Guan Y, Peiris M, Chen H. H5N1
Influenza Continues To Circulate and Change.
|
|
|
|
Woolhouse, MEJ. Where Do Emgerging Pathogens Come from? (Influenza)
|
|
|
|
Narita M, Tsuji BT, Yu VL. Linezolid
toxicity: Lactic Acidosis, Peripheral and Optic Neuropathy Review.
|
|
|
|
|
 |
